Interferon alfa-2a
Roferon-A (interferon alfa-2a) is a protein pharmaceutical. Interferon alfa-2a was first approved as Roferon-a on 1986-06-04. It is used to treat brain neoplasms, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, and essential thrombocythemia amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| digestive system diseases | D004066 |
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| hemic and lymphatic diseases | D006425 |
| skin and connective tissue diseases | D017437 |
| immune system diseases | D007154 |
Show 1 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon alfa-2a
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Roferon-A | interferon alfa-2a | Hoffmann-La Roche Inc. | N-103145 DISCN | 1986-06-04 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pegasys | Biologic Licensing Application | 2019-11-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| brain neoplasms | EFO_0003833 | D001932 | C71 |
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
| colorectal neoplasms | — | D015179 | — |
| cryoglobulinemia | EFO_0005846 | D003449 | D89.1 |
| essential thrombocythemia | — | D013920 | D47.3 |
| hairy cell leukemia | — | D007943 | C91.4 |
| hemangioma | — | D006391 | D18.0 |
| hepatitis d | EFO_0007304 | D003699 | — |
| hepatocellular carcinoma | — | D006528 | C22.0 |
| hypereosinophilic syndrome | EFO_1001467 | D017681 | D72.11 |
Show 12 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0145 | Injection, pegylated interferon alfa-2a, 180 mcg per ml |
Clinical
Clinical Trials
666 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 6 | 63 | 62 | 61 | 32 | 216 |
| Hepatitis c | D006526 | B19.2 | 6 | 33 | 40 | 23 | 11 | 105 | |
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | 12 | 27 | 18 | 40 | 13 | 102 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 11 | 22 | 10 | 6 | 3 | 47 |
| Hepatitis b | D006509 | — | 5 | 6 | 3 | 8 | 21 | ||
| Neoplasms | D009369 | C80 | 8 | 4 | — | 1 | — | 12 | |
| Hepacivirus | D016174 | — | 7 | 4 | 1 | 1 | 12 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 3 | 2 | 2 | 1 | 8 |
| Chronic hepatitis | D006521 | K73.9 | 1 | 3 | 3 | 1 | — | 7 | |
| Chronic hepatitis d | D019701 | — | 2 | 2 | 1 | — | 5 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 12 | 11 | 8 | — | 1 | 31 | ||
| Renal cell carcinoma | D002292 | 3 | 13 | 3 | — | 1 | 17 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 6 | — | 6 | 12 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | 4 | 5 | — | — | 8 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 5 | 1 | — | — | 7 |
| Polycythemia vera | D011087 | D45 | 1 | 1 | 4 | — | — | 6 | |
| Recurrence | D012008 | 1 | 2 | 3 | — | — | 4 | ||
| Covid-19 | D000086382 | U07.1 | 2 | 3 | 1 | — | — | 3 | |
| Multiple myeloma | D009101 | C90.0 | — | 1 | 2 | — | — | 3 | |
| Primary myelofibrosis | D055728 | D47.4 | 1 | 1 | 1 | — | — | 3 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 3 | — | — | — | 6 |
| Kaposi sarcoma | D012514 | C46 | 3 | 2 | — | — | — | 5 | |
| Leukemia | D007938 | C95 | 2 | 2 | — | — | 1 | 4 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 4 | — | — | — | 4 |
| Hepatitis d | D003699 | EFO_0007304 | — | 3 | — | — | — | 3 | |
| Fibrosis | D005355 | — | 1 | — | — | 2 | 3 | ||
| Prostatic neoplasms | D011471 | C61 | — | 2 | — | — | — | 2 | |
| Adenocarcinoma | D000230 | — | 2 | — | — | — | 2 | ||
| Fallopian tube neoplasms | D005185 | 1 | 2 | — | — | — | 2 | ||
| Uveal neoplasms | D014604 | EFO_1001230 | — | 2 | — | — | — | 2 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 7 | — | — | — | 1 | 8 | ||
| Triple negative breast neoplasms | D064726 | 2 | — | — | — | — | 2 | ||
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intravenous substance abuse | D015819 | — | — | — | — | 1 | 1 | ||
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | 1 | 1 | |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | — | 1 | 1 |
| Ascites | D001201 | HP_0001541 | R18 | — | — | — | — | 1 | 1 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INTERFERON ALFA-2A |
| INN | peginterferon alfa-2a |
| Description | Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be used alone. It is given by injection under the skin.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 198153-51-4 |
| RxCUI | 120608 |
| ChEMBL ID | CHEMBL2108508 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00008 |
| UNII ID | Q46947FE7K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 91 documents
View more details
Safety
Black-box Warning
Black-box warning for: Pegasys
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,773 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more